Frontiers in Oncology (Mar 2023)
Development and validation of nomograms for predicting survival in differentiated thyroid cancer patients with or without radioiodine therapy
Abstract
ObjectiveThis study aimed to establish and validate the nomograms for predicting overall survival (OS) probabilities in differentiated thyroid cancer (DTC) patients who received and did not receive radioiodine therapy (RAI), respectively.MethodsIn this study, 11, 099 patients diagnosed with DTC in the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2016 were selected. Whether they have RAI, they are divided into RAI (n=6427) and non-RAI (n=4672) groups. They were randomly assigned to either a training cohort (RAI: n=4498, non-RAI: n=3263) or a validation cohort (RAI: n=1929, non-RAI: n=1399) using R software to divide the patients in a 7-to-3 ratio randomly. Variables were selected using a backward stepwise method in a Cox regression model to determine the independent prognostic factors, which were then utilized to build two nomograms to predict the 5-, 8-, and 10-year OS probabilities in DTC patients with or without RAI. The concordance index (C‐index), the area under the time-dependent receiver operating characteristics curve (AUC), the net reclassification improvement (NRI), the integrated discrimination improvement (IDI), calibration plotting, and decision-curve analysis (DCA) were used to evaluate the performance of our models.ResultsThe multivariate analyses demonstrated that birth of the year, race, histological type, tumor size, grade, TNM stage, lymph node dissections, surgery, and chemotherapy were risk factors for OS. Compared to the AJCC stage, the C‐index (RAI: training group: 0.911 vs. 0.810, validation group: 0.873 vs. 0.761; non-RAI: training group: 0.903 vs. 0.846, validation group: 0.892 vs. 0.808). The AUC values for the training cohort (RAI: 0.940, 0.933, and 0.942; non-RAI: 0.891, 0.884, and 0.852 for the 5-, 8-, and 10-year OS, respectively) and validation cohort (RAI: 0.855, 0.825, and 0.900, non-RAI: 0.867, 0.896, and 0.899), and the calibration plots of both two models all exhibited better performance. Additionally, the NRI and IDI further showed that they exhibited good 5-, 8-, and 10-year net benefits.ConclusionWe have established the prediction models of DTC patients with or without RAI respectively through various variables. The nomogram may be more targeted to guide clinical decisions in the future.
Keywords
